X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the licensing agreement, Zambon will commercialize IPX203, an oral formulation of carbidopa/levodopa extended-release capsules designed for the treatment of Parkinson’s disease.
Lead Product(s): Carbidopa,Etilevodopa
Therapeutic Area: Neurology Product Name: IPX203
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Amneal Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 27, 2024
Details:
L-CsA-i (Liposomal Cyclosporine A) is a novel, inhaled therapy administered via the optimized investigational eFlow® Technology nebulizer system (PARI Pharma GmbH) for the treatment of BOS in adults following single lung (BOSTON-1) or double lung (BOSTON-2) transplantation.
Lead Product(s): Liposomal Cyclosporine A
Therapeutic Area: Immunology Product Name: L-CsA
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pari
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2023
Details:
Under the agreement, Newron and Zambon have ended their plans to run a clinical trial to test Xadago (safinamide) for uncontrolled movements induced by levodopa in people with Parkinson’s disease.
Lead Product(s): Safinamide Mesylate
Therapeutic Area: Neurology Product Name: Xadago
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Newron Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 15, 2023
Details:
Colistimethate sodium (CMS) is a pro-drug (the form used for inhalation therapy) of the antibiotic colistin. Colistin is a polymyxin antibiotic derived from Bacillus polymyxa var. colistinus.
Lead Product(s): Colistimethate Sodium
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Promixin
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2022
Details:
Promixin (Colistimethate Sodium) is an investigational treatment being developed as a potential first-in-class inhaled therapy for adult patients with NCFB colonized with P. aeruginosa; NCFB is a chronic, progressive, and irreversible respiratory disease.
Lead Product(s): Colistimethate Sodium
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Promixin
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2022
Details:
AB21 (KABP022) formula, consisting of four specific probiotic strains, produces significant positive effects in COVID-19 outpatients, with benefits on remission rate, symptom duration and viral load.
Lead Product(s): KABP022,KABP023,KABP033
Therapeutic Area: Infections and Infectious Diseases Product Name: AB21
Highest Development Status: UndisclosedProduct Type: Large molecule
Recipient: Ab-Biotics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2022
Details:
Through the agreement, the company grants Zambon exclusive rights to commercialize Rivalif (rivastigmine), a multi-day transdermal patch for the treatment of Alzheimer’s disease.
Lead Product(s): Rivastigmine
Therapeutic Area: Neurology Product Name: Rivalif
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Luye Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 10, 2021
Details:
Data shows inhalation via the I-neb ® Adaptive Aerosol Delivery System of Promixin (colistimethate sodium) results in reduction of pulmonary exacerbations in non-cystic fibrosis bronchiectasis (NCFB) patients compared to placebo.
Lead Product(s): Colistimethate Sodium
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Promixin
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2021
Details:
Under the agreement, Newron will sponsor the study and be responsible for Xadago (safinamide), development and execution, as well as leading on all related regulatory interactions. Newron and Zambon will evenly share the cost of the study.
Lead Product(s): Safinamide Mesylate
Therapeutic Area: Neurology Product Name: Xadago
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Newron Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 12, 2021
Details:
FDA has granted Fast Track designation to Liposomal Cyclosporine A for Inhalation (L‑CsA‑i), in late-stage clinical development for the treatment of Bronchiolitis Obliterans Syndrome.
Lead Product(s): Cyclosporine
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
